JP7600135B2 - 組換えｃｃｎドメインタンパク質および融合タンパク質 - Google Patents

組換えｃｃｎドメインタンパク質および融合タンパク質 Download PDF

Info

Publication number
JP7600135B2
JP7600135B2 JP2021556442A JP2021556442A JP7600135B2 JP 7600135 B2 JP7600135 B2 JP 7600135B2 JP 2021556442 A JP2021556442 A JP 2021556442A JP 2021556442 A JP2021556442 A JP 2021556442A JP 7600135 B2 JP7600135 B2 JP 7600135B2
Authority
JP
Japan
Prior art keywords
seq
protein
sequence
amino acid
proteins
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021556442A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022525661A (ja
JPWO2020188081A5 (https=
JP2022525661A5 (https=
Inventor
アットラマダル，ホーバード
カースボール，オーレ・ユルゲン
Original Assignee
オスロ ウニヴェルスィテーツスィーケフース ホーエフ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by オスロ ウニヴェルスィテーツスィーケフース ホーエフ filed Critical オスロ ウニヴェルスィテーツスィーケフース ホーエフ
Publication of JP2022525661A publication Critical patent/JP2022525661A/ja
Publication of JPWO2020188081A5 publication Critical patent/JPWO2020188081A5/ja
Publication of JP2022525661A5 publication Critical patent/JP2022525661A5/ja
Application granted granted Critical
Publication of JP7600135B2 publication Critical patent/JP7600135B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
JP2021556442A 2019-03-20 2020-03-20 組換えｃｃｎドメインタンパク質および融合タンパク質 Active JP7600135B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19163970.7 2019-03-20
EP19163970.7A EP3711772A1 (en) 2019-03-20 2019-03-20 Recombinant proteins and fusion proteins
PCT/EP2020/057773 WO2020188081A1 (en) 2019-03-20 2020-03-20 Recombinant ccn domain proteins and fusion proteins

Publications (4)

Publication Number Publication Date
JP2022525661A JP2022525661A (ja) 2022-05-18
JPWO2020188081A5 JPWO2020188081A5 (https=) 2023-03-28
JP2022525661A5 JP2022525661A5 (https=) 2023-03-28
JP7600135B2 true JP7600135B2 (ja) 2024-12-16

Family

ID=66102364

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021556442A Active JP7600135B2 (ja) 2019-03-20 2020-03-20 組換えｃｃｎドメインタンパク質および融合タンパク質

Country Status (12)

Country Link
US (1) US12606602B2 (https=)
EP (2) EP3711772A1 (https=)
JP (1) JP7600135B2 (https=)
KR (1) KR20210142681A (https=)
CN (1) CN113747912B (https=)
AU (1) AU2020243073B2 (https=)
BR (1) BR112021017147A2 (https=)
CA (1) CA3133740A1 (https=)
IL (1) IL285930B2 (https=)
MX (1) MX2021011407A (https=)
SG (1) SG11202109738QA (https=)
WO (1) WO2020188081A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4259648A4 (en) * 2020-12-08 2025-03-26 Seattle Children's Hospital (DBA Seattle Children's Research Institute) Chimeric anti-EGFR antigen receptors
GB202212077D0 (en) 2022-08-18 2022-10-05 Tribune Therapeutics Ab Agents that inhibit ccn ligand-induced signalling for treating disease
GB202400055D0 (en) * 2024-01-03 2024-02-14 Tribune Therapeutics Ab Use of ccn domain-containing proteins for the treatment of disease

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005040191A2 (en) 2003-06-20 2005-05-06 Munin Corporation Ccn1 compositions and methods
JP2007501203A (ja) 2003-08-01 2007-01-25 サントル ナシオナル ドゥ ラ ルシェルシェ シアンティフィク 新規抗血管新生剤及びその使用、特には癌の治療における使用
JP2012528812A (ja) 2009-06-04 2012-11-15 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト ヒトｃｃｎ１に対する抗体とその用途
JP2018513124A (ja) 2015-03-12 2018-05-24 メディミューン，エルエルシー アルブミン融合タンパク質を精製する方法
JP2018517708A (ja) 2015-06-05 2018-07-05 ニューヨーク・ユニバーシティ 抗ブドウ球菌生物学的薬剤のための組成物及び方法
JP2018536657A (ja) 2015-07-20 2018-12-13 イェナゴン セラピューティクス アーベー Ｇｄｆ１５の活性を低減させるための試薬

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT88641B (pt) 1987-10-02 1993-04-30 Genentech Inc Metodo para a preparacao de uma variante de adesao
GB8909916D0 (en) 1989-04-29 1989-06-14 Delta Biotechnology Ltd Polypeptides
FR2650598B1 (fr) 1989-08-03 1994-06-03 Rhone Poulenc Sante Derives de l'albumine a fonction therapeutique
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
WO1999047556A2 (en) * 1998-03-19 1999-09-23 Trustees Of Tufts College Novel heparin-induced ccn-like molecules and uses therefor
JP4202128B2 (ja) * 2000-10-16 2008-12-24 ジェネンテック・インコーポレーテッド Ｗｉｓｐポリペプチドを用いる治療方法
EP1771467A2 (en) 2004-07-26 2007-04-11 Asterion Limited Linkers
ES2395260T3 (es) * 2005-01-10 2013-02-11 Rosalind Franklin University Of Medicine And Science Proteína CCN3 para su utilización en el tratamiento y el diagnóstico de enfermedades renales
DK1853631T3 (en) * 2005-01-24 2016-03-29 Univ Texas Fc-FUSION CONSTRUCTIONS BINDING TO PHOSPHATIDYLSERINE AND THERAPEUTIC APPLICATION THEREOF
US20100144641A1 (en) 2005-09-12 2010-06-10 Popel Aleksander S Compositions Having Antiangiogenic Activity and Uses Thereof
JP2009067678A (ja) * 2005-12-07 2009-04-02 Nihon Nosan Kogyo Kk 結合組織増殖因子に対する抗体又はそれを含む組成物
US20080207489A1 (en) 2007-02-21 2008-08-28 John Castellot Use of CCN5 for treatment of smooth muscle proliferation disorders
WO2009086132A2 (en) 2007-12-20 2009-07-09 University Of Southern California Design of spacers to increase the expression of recombinant fusion proteins
DK3061817T3 (en) * 2009-04-30 2019-03-04 Kao Corp Alkaline protease variants
CA2773737C (en) 2009-09-09 2021-11-16 Pharmain Corporation Anionic-core composition for delivery of therapeutic agents, and methods of making and using the same
ES2688978T3 (es) 2009-11-23 2018-11-07 Amgen Inc. Anticuerpo monomérico Fc
KR101187814B1 (ko) 2010-03-22 2012-10-08 광주과학기술원 심부전 예방 또는 치료용 약제학적 조성물 및 심부전 예방 또는 치료제의 스크리닝 방법
EP2552462B1 (en) 2010-04-02 2015-12-16 Rosalind Franklin University of Medicine and Science Ccn3 peptides and analogs thereof for therapeutic use
US9114112B2 (en) * 2010-04-02 2015-08-25 Rosalind Franklin University Of Medicine And Science CCN3 and CCN3 peptides and analogs thereof for therapeutic uses
ES2630031T3 (es) * 2010-09-28 2017-08-17 Aegerion Pharmaceuticals, Inc. Un polipéptido de leptina pinnípedo-humano quimérico con solubilidad aumentada
CA2822366A1 (en) 2010-12-23 2012-06-28 Janssen Biotech, Inc. Active protease-resistant antibody fc mutants
WO2014008582A1 (en) 2012-07-11 2014-01-16 The University Of Western Ontario Method of treating wounds with penostin and/or ccn2
US20140271641A1 (en) 2013-03-14 2014-09-18 University Of Guelph Thrombospondin-1 polypeptides and methods of using same
GB201316592D0 (en) 2013-09-18 2013-10-30 Levicept Ltd Fusion protein
CN105396136B (zh) * 2015-11-23 2018-10-30 上海交通大学医学院附属第九人民医院 CCN1（Cyr61）在治疗皮肤损伤及皮肤萎缩相关疾病中的应用
EP3192806A1 (en) 2016-01-13 2017-07-19 Affiris AG Alpha chain of the high-affinity ige receptor (fceria)
AU2017232546B2 (en) 2016-03-14 2024-05-02 Universitetet I Oslo Engineered immunoglobulins with altered FCRN binding
US10028906B2 (en) 2016-03-22 2018-07-24 Rosalind Franklin University Of Medicine And Science Method and kit for treating a solid tumor and associated desmoplasia
EP3494128B1 (en) 2016-08-04 2023-11-29 Stichting VUmc Embryonic angiogenesis markers and diagnostic and therapeutic strategies based thereon
US20180127478A1 (en) 2016-09-16 2018-05-10 Wei-Chiang Shen SINGLE CHAIN Fc-DIMER-HUMAN GROWTH HORMONE FUSION PROTEIN FOR IMPROVED DRUG DELIVERY
KR20180099537A (ko) * 2017-02-28 2018-09-05 주식회사 파이안바이오테크놀로지 근섬유모세포의 병리적 활성이 초래하는 섬유증식성 질병 치료제
KR102008407B1 (ko) 2017-09-05 2019-08-08 한국생명공학연구원 코돈 최적화된 il-21 및 이의 용도
WO2019071007A1 (en) 2017-10-05 2019-04-11 New York Genome Center, Inc. METHODS AND COMPOSITIONS FOR TARGETING VASCULAR MIMETTISM

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005040191A2 (en) 2003-06-20 2005-05-06 Munin Corporation Ccn1 compositions and methods
JP2007501203A (ja) 2003-08-01 2007-01-25 サントル ナシオナル ドゥ ラ ルシェルシェ シアンティフィク 新規抗血管新生剤及びその使用、特には癌の治療における使用
JP2012528812A (ja) 2009-06-04 2012-11-15 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト ヒトｃｃｎ１に対する抗体とその用途
JP2018513124A (ja) 2015-03-12 2018-05-24 メディミューン，エルエルシー アルブミン融合タンパク質を精製する方法
JP2018517708A (ja) 2015-06-05 2018-07-05 ニューヨーク・ユニバーシティ 抗ブドウ球菌生物学的薬剤のための組成物及び方法
JP2018536657A (ja) 2015-07-20 2018-12-13 イェナゴン セラピューティクス アーベー Ｇｄｆ１５の活性を低減させるための試薬

Also Published As

Publication number Publication date
EP3711772A1 (en) 2020-09-23
MX2021011407A (es) 2022-01-24
CN113747912A (zh) 2021-12-03
US20220144903A1 (en) 2022-05-12
US12606602B2 (en) 2026-04-21
WO2020188081A1 (en) 2020-09-24
AU2020243073A1 (en) 2021-11-11
CN113747912B (zh) 2025-04-04
IL285930B2 (en) 2025-01-01
BR112021017147A2 (pt) 2021-11-09
JP2022525661A (ja) 2022-05-18
SG11202109738QA (en) 2021-10-28
EP3941507A1 (en) 2022-01-26
IL285930A (en) 2021-10-31
CA3133740A1 (en) 2020-09-24
AU2020243073B2 (en) 2025-06-05
KR20210142681A (ko) 2021-11-25
IL285930B1 (en) 2024-09-01

Similar Documents

Publication Publication Date Title
TWI513705B (zh) 纖維母細胞生長因子２１蛋白質
JP7600135B2 (ja) 組換えｃｃｎドメインタンパク質および融合タンパク質
TW201938186A (zh) Il-22 fc融合蛋白及使用方法
JP2634323B2 (ja) Ｔｃｆ‐▲ｉｉ▼のアミノ酸配列をコードするｄｎａを含むプラスミド，形質転換細胞及びこれを用いて生理活性物質を生産する方法
KR20170049319A (ko) 지속형 fgf21 융합 단백질 및 이를 포함하는 약학적 조성물
JP2018535964A (ja) 線維芽細胞増殖因子（ｆｇｆ）１アナログによるステロイド誘導性高血糖の処置
AU2016332062A1 (en) Treatment of bile acid disorders
CN1088616A (zh) 大潜在转化生长因子-β复合物及其有用结构物的生产方法
WO2010074081A1 (ja) 三重螺旋構造を有するタンパク質、およびその製造方法
CN104974262B (zh) 重组双功能融合蛋白及其制法和用途
US20170334971A1 (en) Alpha-1-Antitrypsin (A1AT) Fusion Proteins and Uses Thereof
EP1978994B1 (en) Bmp-7 variant compositions, methods and uses
RU2825102C2 (ru) Рекомбинантные белки с доменами ccn и слитые белки
KR20220006013A (ko) 보체 경로 억제제를 포함하는 융합단백질 및 이의 용도
WO2008014054A2 (en) Bmp-7 variant compositions, methods and uses
CN113527506A (zh) 融合蛋白及其应用
KR20160013730A (ko) 세포투과성이 우수한 ｔａｔ－ａ２０ 융합단백질의 제조방법 및 이의 용도
CN108424459A (zh) 人血清白蛋白与人突变型肝细胞生长因子的融合蛋白及其制备方法和应用
WO2015161832A1 (zh) 长效重组人干扰素α2b-Fc融合蛋白
JPS62285788A (ja) 新規ベクタ−

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230317

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230317

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240307

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240605

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240807

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20240807

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20241118

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20241204

R150 Certificate of patent or registration of utility model

Ref document number: 7600135

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150